Company Analysis JW (Cayman) Therapeutics Co. Ltd
1. Summary
Disadvantages
- Price (0.255 $) is higher than fair price (0.2225 $)
- Dividends (0%) are below the sector average (1.76%).
- The stock's return over the last year (-39.37%) is lower than the sector average (-7.41%).
- Current debt level 12.98% has increased over 5 years from 9.11%.
- The company's current efficiency (ROE=-45.61%) is lower than the sector average (ROE=13.23%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| JW (Cayman) Therapeutics Co. Ltd | Healthcare | Index | |
|---|---|---|---|
| 7 days | -4.6% | 0.2% | 0.6% |
| 90 days | -20.6% | -7.3% | 2.5% |
| 1 year | -39.4% | -7.4% | 25.6% |
JWCTF vs Sector: JW (Cayman) Therapeutics Co. Ltd has significantly underperformed the "Healthcare" sector by -31.96% over the past year.
JWCTF vs Market: JW (Cayman) Therapeutics Co. Ltd has significantly underperformed the market by -64.96% over the past year.
Stable price: JWCTF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: JWCTF with weekly volatility of -0.7571% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (0.255 $) is higher than the fair price (0.2225 $).
Price is higher than fair: The current price (0.255 $) is 12.7% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (31.94).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (46.66).
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.4665) is lower than that of the sector as a whole (3.37).
P/BV vs Market: The company's P/BV (0.4665) is higher than that of the market as a whole (-9.04).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.52) is higher than that of the sector as a whole (3.27).
P/S vs Market: The company's P/S indicator (4.52) is lower than that of the market as a whole (4.84).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-0.2077) is lower than that of the sector as a whole (10.05).
EV/Ebitda vs Market: The company's EV/Ebitda (-0.2077) is lower than that of the market as a whole (25.09).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -10.77% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-10.77%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-52.93%).
5.4. ROE
ROE vs Sector: The company's ROE (-45.61%) is lower than that of the sector as a whole (13.23%).
ROE vs Market: The company's ROE (-45.61%) is lower than that of the market as a whole (-8.19%).
5.5. ROA
ROA vs Sector: The company's ROA (-35.79%) is lower than that of the sector as a whole (6.16%).
ROA vs Market: The company's ROA (-35.79%) is lower than that of the market as a whole (4.87%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.76%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
